Novartis Pharma AG: Novartis Scemblix demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix (asciminib) vs. Bosulif* (bosutinib) and lower discontinuation rate due to adverse

Related Keywords

United States ,East Hanover ,Pennsylvania ,Philadelphia ,America ,American ,Isabella Zinck ,Jeff Legos ,Thomas Hungerbuehler ,Floriana Riccio Furnari ,Michaelj Mauro ,Samir Shah ,Parag Mahanti ,Julie Masow ,Sloan Simpson ,Alina Levchuk ,Novartis Oncology Congress Hub ,Twitter ,Novartis Oncology Communications ,Novartis Us External Communications ,Novartis External Communications ,Novartis ,Exchange Commission ,Pfizer ,Approval Program ,American Society Of Hematology Annual Meeting Exposition ,Novartis Pharmaceuticals Corp ,American Society ,Hematology Annual Meeting ,Myeloproliferative Neoplasms Program Leader ,Memorial Sloan Kettering Cancer Center ,Executive Vice President ,Global Head ,Hematology Development ,Novartis Commitment ,Prescribing Information ,Safety Results ,Chronic Myeloid Leukemia ,Chronic Phase ,Tyrosine Kinase Inhibitors ,Randomized Study ,Provides Durable Molecular Response ,Primary Efficacy ,Allosteric Inhibitor ,Tyrosine Kinase Activity ,Reveals Significant ,Durable Responses ,Exhibits Safety ,Phasei Study ,Asciminib Plus Nilotinib ,Therapy Using Asciminib Plus Imatinib ,Previously Treated With ,Adult Patients With Newly Diagnosed ,More Tyrosine Kinase ,Patients With ,Pediatric Patients With Chronic Myeloid Leukemia ,Treatment Optimization ,Open Label ,Once Daily ,Newly Diagnosed Adult Patients ,Pediatric Patients ,Chronic Phase Treated ,Tyrosine Kinase ,Dharma ,Scemblix ,Emonstrates ,Sustained ,Response ,Gate ,Eek ,Follow ,Patients ,Hronic ,Amyeloid ,Leukemia ,